Diagnosis and monitoring of nonalcoholic steatohepatitis: current state and future directions
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, with a worldwide
prevalence of 25%. NAFLD is a spectrum that includes nonalcoholic fatty liver defined …
prevalence of 25%. NAFLD is a spectrum that includes nonalcoholic fatty liver defined …
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Keyur Patel1, Sumeet K Asrani2, Maria Isabel Fiel3, Deborah Levine4, Daniel H. Leung5,
Andres Duarte-Rojo6, Jonathan A. Dranoff7 Page 1 Accuracy of blood-based biomarkers for …
Andres Duarte-Rojo6, Jonathan A. Dranoff7 Page 1 Accuracy of blood-based biomarkers for …
The effect of testosterone replacement therapy on nonalcoholic fatty liver disease in older hypogonadal men
Context Male hypogonadism is associated with visceral obesity and the metabolic
syndrome: factors important for the development of nonalcoholic fatty liver disease (NAFLD) …
syndrome: factors important for the development of nonalcoholic fatty liver disease (NAFLD) …
[HTML][HTML] Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
A Stefanska, K Bergmann, S Suwała… - Metabolites, 2024 - mdpi.com
Metabolic dysfunction-associated fatty liver disease (MAFLD) may progress to advanced
liver fibrosis (ALF). We evaluated the diagnostic accuracy of a novel Liver Fibrosis Risk …
liver fibrosis (ALF). We evaluated the diagnostic accuracy of a novel Liver Fibrosis Risk …
Within‐individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test
MP McRae, J Kittelson, SM Helmke… - Clinical and …, 2024 - Wiley Online Library
Current noninvasive liver tests measure fibrosis, inflammation, or steatosis and do not
measure function. The HepQuant platform of noninvasive tests uniquely assesses both liver …
measure function. The HepQuant platform of noninvasive tests uniquely assesses both liver …
Non-invasive tests for alcohol-associated liver disease
M Israelsen, W Rungratanawanich, M Thiele… - Hepatology, 2024 - journals.lww.com
Alcohol consumption is a global phenomenon and a major contributor to alcohol-associated
liver disease (ALD). Detecting individuals at risk of ALD has been challenging, with only a …
liver disease (ALD). Detecting individuals at risk of ALD has been challenging, with only a …
[HTML][HTML] Non-invasive serum biomarkers for the diagnosis of cirrhosis in patients with autoimmune hepatitis (AIH) and AIH-primary biliary cholangitis overlap syndrome …
S Nawalerspanya, J Tantipisit, S Assawasuwannakit… - Diagnostics, 2024 - mdpi.com
Several serum biomarkers for fibrosis assessment have been proposed in various liver
diseases, but in autoimmune hepatitis (AIH) or overlap with primary biliary cholangitis (PBC; …
diseases, but in autoimmune hepatitis (AIH) or overlap with primary biliary cholangitis (PBC; …
[HTML][HTML] Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients
The aim of this review is to provide updated information on the clinical use of non-invasive
serum and imaging-based tests for fibrosis assessment in chronic hepatitis B (CHB) virus …
serum and imaging-based tests for fibrosis assessment in chronic hepatitis B (CHB) virus …
[HTML][HTML] Palm-Sized Wireless Transient Elastography System with Real-Time B-Mode Ultrasound Imaging Guidance: Toward Point-of-Care Liver Fibrosis Assessment
ZH Huang, LK Wang, SY Cai, HX Chen, Y Zhou… - Diagnostics, 2024 - mdpi.com
Transient elastography (TE), recommended by the WHO, is an established method for
characterizing liver fibrosis via liver stiffness measurement (LSM). However, technical …
characterizing liver fibrosis via liver stiffness measurement (LSM). However, technical …
[HTML][HTML] Serum dithiothreitol-oxidizing capacity (DOC) is a promising biomarker for excluding significant liver fibrosis: a proof-of-concept study
L Yang, Y Zhang, X Hong, K Zhang, B Liu, P Zhang… - BMC medicine, 2024 - Springer
Background APRI and FIB-4 scores are used to exclude clinically significant fibrosis (defined
as stage≥ F2) in patients with chronic viral hepatitis. However, the cut-offs for these scores …
as stage≥ F2) in patients with chronic viral hepatitis. However, the cut-offs for these scores …